Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
VA San Diego Health Care System, San Diego, California, United States
Henry Ford Hospital, Detroit, Michigan, United States
HFH Main campus, Detroit, Michigan, United States
Sentara Norfolk General Emergency Department, Norfolk, Virginia, United States
Jones Institue Clinical Research Center, Norfolk, Virginia, United States
Over 50 countries Worldwide, London, United Kingdom
Tribhuvan University Teaching Hospital, Kathmandu, Kathmandy, Nepal
Colombian foundation center for epilepsy and neurological disease, Cartagena, Bolivar, Colombia
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Manee Raksakietisak, Bangkok, Thailand
UZ Pellenberg, Pellenberg, Belgium
Pusat Perubatan University Malaya, Petaling Jaya, Selangor, Malaysia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.